Not registered yet? Please contact our project assistant Dennis Cleff . This area is only for members of the research consortium.

European Foundation for the Study of Chronic Liver Failure

Travessera de Gràcia 11
7th floor
08021 Barcelona
Visit website

Team Leader

Prof. Dr. Richard Moreau

Phone: +34 932 271 400
Send message

Prof. Dr. Pierre-Emmanuel Rautou

Professor of Hepatology, Scientific Coordinator DECISION, Member of the EASL-CLIF Consortium Steering Committee
Phone: +33 140 875 283
Send message

Team Staff

Dr. Anna Bosch

General Manager
Phone: +34 932 271 403
Send message

Dr. Lidia Garcia-Campmany

Scientific Communications Manager
Phone: +34 932 271 407
Send message

Cristina Sanchez Garrido

Head of the Data Manager Center
Phone: +34 932 271 400
Send message

Ferran Aguilar

Phone: +34 932 271 400
Send message

Carlos de la Peña-Ramirez

Send message

Eva Usón

Send message

Pedro Izquierdo-Bueno Martín

Send message

Institute Presentation

The European Foundation for the Study of Chronic Liver Failure (EF CLIF) is a private nonprofit organization which mission is to promote research and education in chronic liver disease with the aim to contribute to improving the quality of life and to increase the survival of patients with cirrhosis.

EF CLIF has made pioneering efforts in conducting a series of large, international prospective studies that have been instrumental in reclassifying the trajectory of patients with chronic liver failure and led to the clinical, prognostic and pathophysiological definition of the syndrome referred to as “acute-on-chronic liver failure” (ACLF) characterized by acute decompensation of cirrhosis, severe systemic inflammation, organ failures, and high short-term mortality.


Since its foundation in 2009, the European Association for the Study of the Liver (EASL) Chair supports research activities through the EASL-CLIF Consortium, a network of 116 tertiary level university hospitals in 28 European countries. The EASL Chair promotes research in liver disease in Europe through a collaborative effort aimed at furthering the knowledge and understanding of the mechanisms underlying cirrhosis and its complications. The EASL-CLIF Consortium provides the framework to conduct ancillary studies and clinical trials that will lead to evaluate new therapies in cirrhosis, establish diagnostic criteria, and identify predictors for the design of new prognostic scores for acute-on-chronic liver failure to improve the quality of life and survival of current and future patients with cirrhosis.

The Grifols Chair promotes translational studies across centers throughout Europe and North America within the framework of the European Network for Translational Research (ENTR) with 25 centers in 8 countries. The Grifols Chair promotes research aimed at characterizing the mechanisms underlying the presence of systemic inflammation in patients with decompensation of cirrhosis and its role in the development of acute-on-chronic liver failure.

More recently, the establishment of the Global Projects chapter has enabled to establish connections between healthcare professionals and experts over the world to further the understanding of the epidemiology and pathophysiology of ACLF. Through collaborative research, the Global Projects also aim to identify novel biomarkers and therapeutic targets in cirrhosis and develop guidelines that will contribute to minimize regulatory barriers and facilitate better outcomes and quality of life for patients with chronic liver disease worldwide.

EF CLIF also partners with industry to address unmet medical needs in cirrhosis and generate insights to drive innovative therapeutic solutions that can transform and revolutionize patient care.

The Data Management Center enables access to specimens and relevant clinical and laboratory data, and provides bioinformatics and statistical analysis expertise.


Within DECISION, EF CLIF coordinates the project (WP8) and will lead the process of integration of clinical and biological sample data from the CANONIC, PREDICT, and ACLARA studies (WP2). Moreover, EF CLIF will participate in the study design and perform statistical analyses of the proof-of-concept trial described in WP5.